Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Edward Mikula

Physician Assistant, Medical Baltimore, MD Physician Assistant

NPI 1639506165 CMS profile 10841890

301 St. Paul Place, Heart Center At Mercy, Baltimore, MD 21202

Open in the dashboard

General payments

$11,139

506 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Mikula of Baltimore, MD is reported in the CMS Open Payments database as having received $11,139 across 506 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,071 93
2024 General $2,592 124
2023 General $2,482 114
2022 General $2,262 96
2021 General $1,732 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Mikula
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Edward Mikula were reported at $2,071. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Edward Mikula Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,732 $156 $41–$563 $132
2022 $2,262 $185 $55–$649 $149
2023 $2,482 $199 $58–$717 $160
2024 $2,592 $206 $62–$740 $164
2025 $2,071 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,476 91 payments
  2. Abbott Laboratories $1,220 25 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $932 39 payments
  4. AstraZeneca Pharmaceuticals LP $831 43 payments
  5. Pfizer Inc. $757 42 payments
  6. Amgen Inc. $655 29 payments
  7. Janssen Pharmaceuticals, Inc $523 23 payments
  8. Merck Sharp & Dohme Corporation $504 29 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $491 17 payments
  10. Novo Nordisk Inc $365 16 payments
  11. Other $3,386 152 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,984 503 payments
  2. Education $156 3 payments
Products named General payments · program years 2021–2025
  1. LEQVIO $688 38 payments
  2. VERQUVO $629 36 payments
  3. XARELTO $523 23 payments
  4. LifeVest $491 17 payments
  5. JOT DX $486 9 payments
  6. ENTRESTO $480 31 payments
  7. Repatha $463 21 payments
  8. JARDIANCE Diabetes $462 20 payments
  9. ELIQUIS $462 27 payments
  10. JARDIANCE Diabetes $443 18 payments
  11. Other $6,819 312 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,384

Median for Physician Assistant: 241

Drug cost

$371,196

Median for Physician Assistant: $4,110

Branded share of claims

27.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 115 $147,239
Repatha Sureclick Evolocumab Brand 109 $73,110
Entresto Sacubitril/Valsartan Brand 31 $50,731
Xarelto Rivaroxaban Brand 32 $43,932
Jardiance Empagliflozin Brand 18 $22,933
Praluent Pen Alirocumab Brand 14 $16,199
Metoprolol Succinate Generic 172 $3,068
Atorvastatin Calcium Generic 104 $2,172
Rosuvastatin Calcium Generic 67 $2,141
Amiodarone Hcl Generic 58 $1,834

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$8,634

Medicare's payments for the services billed

Medicare patients

87

Average age 74

Services billed

165

46 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 67%
Chronic kidney disease 61%
Diabetes 57%
Arthritis 57%
Atrial fibrillation 49%
COPD 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $279
$279 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $258
$258 18 —
ELIQUIS
  • PFIZER INC. $161
  • E.R. Squibb & Sons, L.L.C. $84
$245 115 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $181
$181 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $159
$159 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

506 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record